0001193125-12-208753.txt : 20120503
0001193125-12-208753.hdr.sgml : 20120503
20120503165424
ACCESSION NUMBER: 0001193125-12-208753
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120331
FILED AS OF DATE: 20120503
DATE AS OF CHANGE: 20120503
EFFECTIVENESS DATE: 20120503
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BB BIOTECH AG
CENTRAL INDEX KEY: 0000924223
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-06964
FILM NUMBER: 12810502
BUSINESS ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
BUSINESS PHONE: 411724 59 59
MAIL ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
13F-HR
1
d345706d13fhr.txt
FORM 13F-HR
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for Calendar Year or Quarter Ended: March 31, 2012
Check here if Amendment [_]; Amendment Number:
This Amendment (Check only one.): [_] is a restatement.
[_] adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: BB Biotech AG
Address: Vordergasse 3
Schaffhausen Switzerland CH-8200
Form 13F File Number: 28-6964
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Pascal Schmucki
Title: SIGNING AUTHORITY
-----------------
Phone: 41 (44) 267 67 00
Signature, Place, and Date of Signing: /s/ Pascal Schmucki
--------------------------------------
Schaffhausen, Switzerland, May 2, 2012
Report Type (Check only one.):
[X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager
are reported in this report.)
[_] 13F NOTICE. (Check here if no holdings reported are in this report, and all
holdings are reported by other reporting manager(s).)
[_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this
reporting manager are reported in this report and a portion are reported by
other reporting manager(s).)
Form 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 3
Form 13F Information Table Entry Total: 20
Form 13F Information Table Value Total: $1,014,110
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
No. Form 13F File Number Name
--- -------------------- ----
1 28-11193 Biotech Focus N.V.
2 28-11191 Biotech Invest N.V.
3 28-11189 Biotech Target N.V.
2
BB BIOTECH AG
FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
----------------------------- -------- -------- --------- ------------------ ---------- -------- ---------------------
VOTING AUTHORITY
TITLE OF VALUE SHS OR SH/ PUT/ INVESTMENT OTHER ---------------------
NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE
----------------------------- -------- --------- -------- --------- --- ---- ---------- -------- --------- ------ ----
Achillion Pharmaceuticals Inc COM 00448Q201 15,130 1,579,340 SH DEFINED 3 1,579,340 NONE NONE
Alexion Pharmaceuticals Inc COM 015351109 41,787 450,000 SH DEFINED 2 450,000 NONE NONE
Amylin Pharmaceuticals Inc COM 032346108 57,992 2,323,391 SH DEFINED 2 2,323,391 NONE NONE
Ariad Pharmaceuticals Inc COM 04033A100 49,591 3,103,331 SH DEFINED 3 3,103,331 NONE NONE
Biomarin Pharmaceutical Inc COM 09061G101 33,412 975,545 SH DEFINED 2 975,545 NONE NONE
Celgene Corp COM 151020104 201,552 2,600,000 SH DEFINED 2 2,600,000 NONE NONE
Dendreon Corp COM 24823Q107 16,244 1,524,500 SH DEFINED 2 1,524,500 NONE NONE
Endocyte Inc COM 29269A102 4,618 927,321 SH DEFINED 3 927,321 NONE NONE
Gilead Sciences Inc COM 375558103 103,095 2,110,000 SH DEFINED 1 2,110,000 NONE NONE
Halozyme Therapeutics Inc COM 40637H109 61,248 4,800,000 SH DEFINED 3 4,800,000 NONE NONE
Human Genome Sciences Inc COM 444903108 16,480 2,000,000 SH DEFINED 2 2,000,000 NONE NONE
Idenix Pharmaceuticals Inc COM 45166R204 13,706 1,400,000 SH DEFINED 3 1,400,000 NONE NONE
Immunogen Inc COM 45253H101 52,758 3,666,300 SH DEFINED 3 3,666,300 NONE NONE
Incyte Corp COM 45337C102 96,114 4,980,000 SH DEFINED 3 4,980,000 NONE NONE
Isis Pharmaceuticals Inc COM 464330109 63,440 7,233,800 SH DEFINED 3 7,233,800 NONE NONE
Onyx Pharmaceuticals Inc COM 683399109 6,217 165,000 SH DEFINED 2 165,000 NONE NONE
Optimer Pharmaceuticals Inc COM 68401H104 20,054 1,442,700 SH DEFINED 3 1,442,700 NONE NONE
Medicines Co COM 584688105 28,471 1,418,600 SH DEFINED 2 1,418,600 NONE NONE
Theravance Inc COM 88338T104 16,443 843,244 SH DEFINED 3 843,244 NONE NONE
Vertex Pharmaceuticals Inc COM 92532F100 115,758 2,822,684 SH DEFINED 3 2,822,684 NONE NONE
3